Spots Global Cancer Trial Database for Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Official Title: Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Study ID: NCT02657889
Study Description
Brief Summary: This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Birmingham, Alabama, United States
GSK Investigational Site, Phoenix, Arizona, United States
GSK Investigational Site, Scottsdale, Arizona, United States
GSK Investigational Site, Los Angeles, California, United States
GSK Investigational Site, San Francisco, California, United States
GSK Investigational Site, Stanford, California, United States
GSK Investigational Site, Washington, District of Columbia, United States
GSK Investigational Site, Deerfield Beach, Florida, United States
GSK Investigational Site, Jacksonville, Florida, United States
GSK Investigational Site, Miami, Florida, United States
GSK Investigational Site, Orlando, Florida, United States
GSK Investigational Site, Chicago, Illinois, United States
GSK Investigational Site, Covington, Louisiana, United States
GSK Investigational Site, Boston, Massachusetts, United States
GSK Investigational Site, Boston, Massachusetts, United States
GSK Investigational Site, Boston, Massachusetts, United States
GSK Investigational Site, Burlington, Massachusetts, United States
GSK Investigational Site, Detroit, Michigan, United States
GSK Investigational Site, Rochester, Minnesota, United States
GSK Investigational Site, Morristown, New Jersey, United States
GSK Investigational Site, New York, New York, United States
GSK Investigational Site, Chapel Hill, North Carolina, United States
GSK Investigational Site, Charlotte, North Carolina, United States
GSK Investigational Site, Cleveland, Ohio, United States
GSK Investigational Site, Oklahoma City, Oklahoma, United States
GSK Investigational Site, Germantown, Tennessee, United States
GSK Investigational Site, Nashville, Tennessee, United States
GSK Investigational Site, San Antonio, Texas, United States
GSK Investigational Site, Charlottesville, Virginia, United States
GSK Investigational Site, Seattle, Washington, United States
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
